Clinical Trial Update: Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on tissue distribution (biodistribution) of F18-FDG labeled autologous bone marrow stem cell therapy in patients with Type 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• F18-FDG labeled ABMSCT

Snippet

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh | Conditions: Diabetes Mellitus, Non-Insulin-Dependent | Phase 1, Phase 2 | Status: COMPLETED